▲ +159.62% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Selecta Biosciences in the last 3 months. The average price target is $6.75, with a high forecast of $13.00 and a low forecast of $2.50. The average price target represents a 159.62% upside from the last price of $2.60.
The current consensus among 7 contributing investment analysts is to buy stock in Selecta Biosciences.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that has completed Phase II clinical trials for the treatment of chronic refractory gout. It also engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. The company has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., BIND Therapeutics, Inc., Asklepios BioPharmaceutical, Inc., and Sarepta Therapeutics, Inc. Selecta Biosciences, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.